Repository logo
 
Publication

Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study

2023-08Journal article Open access
Simple item page
dc.contributor.authorMarques, J.
dc.contributor.authorDuarte-Ramos, F.
dc.contributor.authorFerreira, M. B.
dc.contributor.authorLima, R.
dc.contributor.authorLopes, C.
dc.contributor.authorSokolova, A.
dc.contributor.authorTonin, Fernanda
dc.contributor.authorLoureiro, C. C.
dc.date.accessioned2023-08-23T11:03:31Z
dc.date.available2023-08-23T11:03:31Z
dc.date.issued2023-08
dc.description.abstractAlthough the prevalence of severe asthma is not high (5–10% of patients), it is responsible for a large part of the overall disease burden and costs (50–60% of total costs), especially if the condition remains uncontrolled (which occurs in around 40% of cases). Currently, for patients without disease control or presenting frequent exacerbations despite optimal therapy, add-on treatments, traditionally long-acting anticholinergics, oral corticosteroids (OCS), or biologic agents (monoclonal antibodies) are recommended. Nonetheless, the long-term use of oral/systemic corticosteroids (CS) is significantly associated with adverse effects, acute and chronic complications that may decrease health-related quality of life and worsen prognosis, thus requiring additional monitoring and management. Conversely, target therapies (i.e., omalizumab, mepolizumab, reslizumab, benralizumab, and more recently, dupilumab) have been developed grounded on the different phenotypes and endotypes of severe asthma, and are gradually reducing the reliance on OCS (i.e., greater specificity for achieving disease control by reducing the risk of exacerbations and requirements for rescue medication and OCS, with limited adverse events).pt_PT
dc.description.sponsorshipThis work was supported by AstraZeneca.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMarques J, Duarte-Ramos F, Ferreira MB, Lima R, Lopes C, Tonin FS, et al. Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study. Pulmonology. 2023;29(6):555-63.pt_PT
dc.identifier.doi10.1016/j.pulmoe.2023.07.003pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/16388
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S2531043723001289pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectAsthmapt_PT
dc.subjectSystemic corticosteroidspt_PT
dc.subjectROSA II Projectpt_PT
dc.subjectPortuguese ROSA Grouppt_PT
dc.titleOptimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus studypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage563pt_PT
oaire.citation.issue6pt_PT
oaire.citation.startPage555pt_PT
oaire.citation.titlePulmonologypt_PT
oaire.citation.volume29pt_PT
person.familyNameTonin
person.givenNameFernanda
person.identifier.ciencia-idD01C-C700-9411
person.identifier.orcid0000-0003-4262-8608
person.identifier.ridO-2050-2017
person.identifier.scopus-author-id56085115800
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication61ded30e-ecec-4b3e-b953-2293e080ebdd
relation.isAuthorOfPublication.latestForDiscovery61ded30e-ecec-4b3e-b953-2293e080ebdd

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project)_a national Delphi consensus study.pdf
Size:
2.88 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos